Association between levels of IgG antibodies from vaccines and Omicron symptomatic infection among children and adolescents in China

Background Measurements of IgG antibodies to wild-type SARS-CoV-2 antigens can assess vaccine efficacy, but the absolute risk of Omicron symptomatic infection at different IgG levels for children and adolescents remains uncertain, as well as the minimum effective antibody level. We sought to determine the relationship between the tertiles of IgG antibodies to wild-type SARS-CoV-2 antigens and children with symptomatic infection of the pandemic and duration to negative conversion in China for the first time. Methods A retrospective study was conducted, including 168 participants under 18 years old from the No.2 People’s Hospital of Lanzhou, China, diagnosed with Omicron variant BA.2.38 between July 8, 2022, and August 2, 2022. We calculated odds ratios (OR) in univariate and multivariate regression to assess the association of symptomatic infection with the tertiles of IgG, respectively. Kaplan–Meier curves and Cox proportional hazards regression were used to evaluate the relationship between IgG level and negative conversion time. Results The average age of the 168 children included in this study was 7.2 (4.7) years old, 133 (79.2%) were symptomatic patients, and the average negative conversion time was 12.2 (3.5) days. The participants with high IgG levels were less likely to become symptomatic, had a shorter turnaround time, and had higher values of IgM and nucleic acid CT. Compared to those with the lowest tertile of IgG, patients with the highest tertile had a 91% lower risk of developing a symptomatic infection after fully adjusting for confounders (OR = 0.09, 95% CI, 0.02-0.36, p = 0.001). There’s no robust relationship between IgG level and negative conversion time in multivariate Cox regression. Conclusion The risk of developing a symptomatic infection can be predicted independently by tertiles of IgG antibodies to wild-type SARS-CoV-2 antigens. High IgG levels can inhibit viral replication, vastly reduce the risk of symptomatic infections and promote a virus-negative conversion, especially when IgG quantitative detection was ≥3.44 S/CO, a potential threshold for protection and booster strategy in the future. More data and research are needed in the future to validate the predictive models.

[1]  M. Kiso,et al.  Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB , 2022, The Lancet Infectious Diseases.

[2]  S. Harrison,et al.  Long-COVID Symptoms in Individuals Infected with Different SARS-CoV-2 Variants of Concern: A Systematic Review of the Literature , 2022, Viruses.

[3]  G. Lippi,et al.  In silico evaluation of the impact of Omicron variant of concern sublineage BA.4 and BA.5 on the sensitivity of RT‐qPCR assays for SARS‐CoV‐2 detection using whole genome sequencing , 2022, Journal of medical virology.

[4]  B. Grunau,et al.  The Relationship Between Anti-Spike SARS-CoV-2 Antibody Levels and Risk of Breakthrough COVID-19 Among Fully Vaccinated Adults , 2022, The Journal of infectious diseases.

[5]  M. Ajelli,et al.  Epidemiological characteristics and transmission dynamics of the outbreak caused by the SARS-CoV-2 Omicron variant in Shanghai, China: A descriptive study , 2022, The Lancet Regional Health - Western Pacific.

[6]  D. Barouch Covid-19 Vaccines — Immunity, Variants, Boosters , 2022, The New England journal of medicine.

[7]  L. Abu-Raddad,et al.  COVID-19 Disease Severity in Persons Infected With Omicron BA.1 and BA.2 Sublineages and Association With Vaccination Status. , 2022, JAMA internal medicine.

[8]  Lu Lu,et al.  Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages , 2022, Signal Transduction and Targeted Therapy.

[9]  Yingxia Liu,et al.  Clinical characteristics and vaccine effectiveness against SARS-CoV-2 Omicron subvariant BA.2 in the children , 2022, Signal Transduction and Targeted Therapy.

[10]  R. Dagan,et al.  Association of Receipt of the Fourth BNT162b2 Dose With Omicron Infection and COVID-19 Hospitalizations Among Residents of Long-term Care Facilities. , 2022, JAMA internal medicine.

[11]  R. Link-Gelles,et al.  Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance. , 2022, JAMA.

[12]  Jiahui Chen,et al.  Omicron BA.2 (B.1.1.529.2): High Potential for Becoming the Next Dominant Variant , 2022, The journal of physical chemistry letters.

[13]  Qiuying Li,et al.  Anti-Receptor-Binding Domain Immunoglobulin G Antibody as a Predictor of Seropositivity for Anti-SARS-CoV-2 Neutralizing Antibody. , 2022, Archives of pathology & laboratory medicine.

[14]  N. Volkow,et al.  Incidence Rates and Clinical Outcomes of SARS-CoV-2 Infection With the Omicron and Delta Variants in Children Younger Than 5 Years in the US. , 2022, JAMA pediatrics.

[15]  P. Zheng,et al.  Humoral immune response of BBIBP COVID‐19 vaccination before and after the booster immunization , 2022, Allergy.

[16]  Q. Ye,et al.  The emergence and epidemic characteristics of the highly mutated SARS‐CoV‐2 Omicron variant , 2022, Journal of medical virology.

[17]  S. Karim,et al.  Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic , 2021, The Lancet.

[18]  Lindsay N. Carpp,et al.  Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial , 2021, Science.

[19]  Youchun Wang Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines , 2021, EBioMedicine.

[20]  M. Davenport,et al.  Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[21]  A. Fiore-Gartland,et al.  Evidence for antibody as a protective correlate for COVID-19 vaccines , 2021, Vaccine.

[22]  P. Zheng,et al.  Characteristics of COVID-19 Patients Based on the Results of Nucleic Acid and Specific Antibodies and the Clinical Relevance of Antibody Levels , 2021, Frontiers in Molecular Biosciences.

[23]  X. Tang,et al.  Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections , 2020, Nature Medicine.

[24]  Satoshi Mimura,et al.  Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis , 2020, The Lancet Infectious Diseases.

[25]  Y. Leo,et al.  Risk Factors for Severe Disease and Efficacy of Treatment in Patients Infected With COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  S. Ng,et al.  Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis , 2020, The Lancet Gastroenterology & Hepatology.

[27]  X. Tang,et al.  Antibody responses to SARS-CoV-2 in patients with COVID-19 , 2020, Nature Medicine.

[28]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[29]  Seung‐Jung Park,et al.  Predictors for functionally significant in-stent restenosis: an integrated analysis using coronary angiography, IVUS, and myocardial perfusion imaging. , 2013, JACC. Cardiovascular imaging.

[30]  Akiko Maehara,et al.  A prospective natural-history study of coronary atherosclerosis. , 2011, The New England journal of medicine.

[31]  P. Fratino,et al.  IDDM in the Province of Pavia, Italy, From a Population-Based Registry: A descriptive study , 1995, Diabetes Care.

[32]  OUP accepted manuscript , 2022, Clinical Infectious Diseases.

[33]  Michel Dückers,et al.  A Systematic Review of the Literature , 2009 .

[34]  S. Jun,et al.  retrospective analysis , 2003 .